Washed microbiota transplantation stopped recurrent sepsis in a patient with myelofibrosis: a case report.

IF 4.3 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Gut Pathogens Pub Date : 2024-12-27 DOI:10.1186/s13099-024-00660-6

Yingqi Yang, Luyao Wang, Tianchi Zhuang, Ting Xu, Minghui Ji, Quan Wang

{"title":"Washed microbiota transplantation stopped recurrent sepsis in a patient with myelofibrosis: a case report.","authors":"Yingqi Yang, Luyao Wang, Tianchi Zhuang, Ting Xu, Minghui Ji, Quan Wang","doi":"10.1186/s13099-024-00660-6","DOIUrl":null,"url":null,"abstract":"Background: Sepsis represents the most prevalent infectious complication and the primary cause of mortality in myeloproliferative neoplasms (MPN). The risk of sepsis and the difficulty of treatment are significantly increased in MPN patients due to the need for immunomodulators and antibiotics.Case presentation: On June 9, 2023, a 69-year-old male was admitted to the hospital. Following a battery of tests, the diagnosis of sepsis due to Escherichia coli was ultimately established. The patient was administered amoxicillin clavulanate potassium intravenously. In light of the patient's recurrent sepsis and the likelihood that the source of infection is the intestinal tract, we advised that the patient undergo washed microbiota transplantation (WMT) via a colonic transendoscopic enteral tube (TET).Conclusions: WMT as the new method of fecal microbiota transplantation (FMT) successfully cured the recurrent sepsis in this case, indicating the novel option for challenging the refractory or serious infections.","PeriodicalId":12833,"journal":{"name":"Gut Pathogens","volume":"16 1","pages":"78"},"PeriodicalIF":4.3000,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673363/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut Pathogens","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13099-024-00660-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sepsis represents the most prevalent infectious complication and the primary cause of mortality in myeloproliferative neoplasms (MPN). The risk of sepsis and the difficulty of treatment are significantly increased in MPN patients due to the need for immunomodulators and antibiotics.

Case presentation: On June 9, 2023, a 69-year-old male was admitted to the hospital. Following a battery of tests, the diagnosis of sepsis due to Escherichia coli was ultimately established. The patient was administered amoxicillin clavulanate potassium intravenously. In light of the patient's recurrent sepsis and the likelihood that the source of infection is the intestinal tract, we advised that the patient undergo washed microbiota transplantation (WMT) via a colonic transendoscopic enteral tube (TET).

Conclusions: WMT as the new method of fecal microbiota transplantation (FMT) successfully cured the recurrent sepsis in this case, indicating the novel option for challenging the refractory or serious infections.

查看原文本刊更多论文

洗净菌群移植治疗骨髓纤维化患者复发性败血症1例。

背景：脓毒症是骨髓增生性肿瘤（MPN）中最常见的感染性并发症和死亡的主要原因。由于需要免疫调节剂和抗生素，MPN患者脓毒症的风险和治疗难度显著增加。病例介绍：2023年6月9日，一名69岁男性住院。经过一系列检查，最终确定了大肠杆菌引起的败血症的诊断。患者静脉给予阿莫西林克拉维酸钾。考虑到患者复发性败血症和感染源可能是肠道，我们建议患者通过结肠经内镜肠内管（TET）进行洗净菌群移植（WMT）。结论：WMT作为粪便微生物群移植（FMT）的新方法成功治愈了该病例的复发性败血症，为挑战难治性或严重感染提供了新的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gut Pathogens GASTROENTEROLOGY & HEPATOLOGY-MICROBIOLOGY

CiteScore

7.70

自引率

2.40%

发文量

期刊介绍： Gut Pathogens is a fast publishing, inclusive and prominent international journal which recognizes the need for a publishing platform uniquely tailored to reflect the full breadth of research in the biology and medicine of pathogens, commensals and functional microbiota of the gut. The journal publishes basic, clinical and cutting-edge research on all aspects of the above mentioned organisms including probiotic bacteria and yeasts and their products. The scope also covers the related ecology, molecular genetics, physiology and epidemiology of these microbes. The journal actively invites timely reports on the novel aspects of genomics, metagenomics, microbiota profiling and systems biology. Gut Pathogens will also consider, at the discretion of the editors, descriptive studies identifying a new genome sequence of a gut microbe or a series of related microbes (such as those obtained from new hosts, niches, settings, outbreaks and epidemics) and those obtained from single or multiple hosts at one or different time points (chronological evolution).